1. Home
  2. DLB vs GRFS Comparison

DLB vs GRFS Comparison

Compare DLB & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolby Laboratories

DLB

Dolby Laboratories

HOLD

Current Price

$63.93

Market Cap

5.8B

Sector

Miscellaneous

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.12

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLB
GRFS
Founded
1965
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.5B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
DLB
GRFS
Price
$63.93
$8.12
Analyst Decision
Strong Buy
Hold
Analyst Count
4
2
Target Price
$90.75
$10.15
AVG Volume (30 Days)
459.3K
588.1K
Earning Date
04-30-2026
07-28-2022
Dividend Yield
2.25%
1.76%
EPS Growth
N/A
N/A
EPS
0.55
N/A
Revenue
N/A
N/A
Revenue This Year
$6.22
$4.49
Revenue Next Year
$3.84
$6.42
P/E Ratio
$116.35
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$57.62
$6.90
52 Week High
$78.28
$11.14

Technical Indicators

Market Signals
Indicator
DLB
GRFS
Relative Strength Index (RSI) 56.98 45.77
Support Level $63.91 $7.52
Resistance Level $64.87 $8.88
Average True Range (ATR) 1.23 0.19
MACD 0.26 -0.02
Stochastic Oscillator 71.17 22.48

Price Performance

Historical Comparison
DLB
GRFS

About DLB Dolby Laboratories

Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: